BioSpace News Archive

Innovent Biologics and LG Chem Life Sciences announced that the two parties have entered into a strategic collaboration and license agreement regarding LG Chem’s Tigulixostat, a late-stage novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.

Prothena Corporation plc announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses.

Sirnaomics Ltd. (the “Company” or “Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the interim results of part-one of an ongoing Phase IIb clinical trial of STP705 for the treatment of Cutaneous Squamous Cell Carcinoma In Situ (isSCC).

MedCognetics, Inc. today announced it has received U.S Food and Drug Administration (FDA) 510(k) clearance of its artificial intelligence (AI)-enabled software for breast cancer screening, QmTRIAGE®.

Valencia Technologies Corporation announced today that the Centers for Medicare & Medicaid Services (CMS), Division of Outpatient Care issued a letter in response to Valencia Technologies’ New Technology APC application stating the eCoin technology did not qualify for a New Technology APC assignment because it is already described by existing CPT® code 64590.

CooperSurgical, Inc., a leader in women’s healthcare, and Ostro, a leading engagement platform dedicated to educating and empowering consumers and healthcare providers, today announced their partnership to launch a new consumer engagement solution for CooperSurgical’s hormone-free IUD, Paragard.

Abivax SA (Euronext Paris:FR0012333284 - ABVX) today announces that its senior executive management will attend the J.P. Morgan 41st Annual Healthcare Conference and the 12th Annual LifeSci Partners Corporate Access Event, both taking place from January 9-12, 2023, in San Francisco, California, US.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with ALG-125755, a small interfering RNA (siRNA) targeting the production of hepatitis B surface antigen (HBsAg), was initiated in subjects with chronic hepatitis B (CHB) in Study ALG-125755-501 (NCT05561530).

Personalis, Inc., a leader in advanced genomics for precision oncology, announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027.